ReviewMolecular therapy. Methods & clinical development2020
Characteristics of the Coronavirus Disease 2019 and related Therapeutic Options.
Review in Molecular therapy. Methods & clinical development, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 35 citations in OpenAlex.
- The impact of COVID-19 pandemic on the incidence, presentation, and management of type 1 diabetes in children and adolescents: a narrative review.Hormones (Athens, Greece) · 2025Review
- The therapeutic potential of gelsolin in attenuating cytokine storm, ARDS, and ALI in severe COVID-19.Frontiers in pharmacology · 2024Review
- Inventory study of an early pandemic COVID-19 cohort in South-Eastern Sweden, focusing on neurological manifestations.PloS one · 2023Observational
- Article
- From Biomedical Applications of Alginate towards CVD Implications Linked to COVID-19.Pharmaceuticals (Basel, Switzerland) · 2022Review
- A Review of Routine Laboratory Biomarkers for the Detection of Severe COVID-19 Disease.International journal of analytical chemistry · 2022Review
- Risk Factors of Symptomatic COVID-19 in Samtse District, Bhutan.Frontiers in public health · 2022Article
- Using artificial intelligence technology to fight COVID-19: a review.Artificial intelligence review · 2022Article
- Lactoferrin as Antiviral Treatment in COVID-19 Management: Preliminary Evidence.International journal of environmental research and public health · 2021Article
- Survival Analysis of Symptomatic COVID-19 in Phuentsholing Municipality, Bhutan.International journal of environmental research and public health · 2021Article
- Potential activity of Linezolid against SARS-CoV-2 using electronic and molecular docking study.Journal of molecular modeling · 2021Article
- Clinical manifestation and disease progression in COVID-19 infection.Journal of the Chinese Medical Association : JCMA · 2021Review
- Role of biomaterials in the diagnosis, prevention, treatment, and study of corona virus disease 2019 (COVID-19).Emergent materials · 2021Review
- A Comprehensive Overview on COVID-19: Future Perspectives.Frontiers in cellular and infection microbiology · 2021Review
- Druggable targets from coronaviruses for designing new antiviral drugs.Bioorganic & medicinal chemistry · 2020Review
- A case report of moderate COVID 19 patient managed through integrative approach (Siddha and conventional medicine).Journal of Ayurveda and integrative medicineArticle
- Integrative management of critical case of Covid 19 withJournal of Ayurveda and integrative medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coronavirus disease 2019 (COVID-19) is a new type of pneumonia caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. COVID-19 is affecting millions of patients, and the infected number keeps increasing. SARS-CoV-2 is highly infectious, has a long incubation period, and causes a relatively high death rate, resulting in severe health problems all over the world. Currently there is no effective proven drug for the treatment of COVID-19; therefore, development of effective therapeutic drugs to suppress SARS-CoV-2 infection is urgently needed. In this review, we first summarize the structure and genome features of SARS-CoV-2 and introduce its infection and replication process. Then, we review the clinical symptoms, diagnosis, and treatment options of COVID-19 patients. We further discuss the potential molecular targets and drug development strategies for treatment of the emerging COVID-19. Finally, we summarize clinical trials of some potential therapeutic drugs and the results of vaccine development. This review provides some insights for the treatment of COVID-19.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.